X

Trial Profile

A Non-interventional Study of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NEPTUN)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms NEPTUN

Most Recent Events

05 Oct 2021 Status changed from active, no longer recruiting to completed.
15 Jun 2021 Planned End Date changed from 1 Jul 2021 to 30 Jul 2021.
31 May 2020 Results of the second interim analysis of the NEPTUN study presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com